Exclusive: Teva, Mylan Eye Pfizer's Brazil Venture, Sources Say
Teva/Mylan: brand management | Financial Times
Mylan surprises analysts, Teva with long-delayed Copaxone approvals | Fierce Pharma
Mylan: no all'offerta di Teva. A meno che non riveda il prezzo... - FarmaciaVirtuale.it
Teva's Generic EpiPen Will Cost As Much As Mylan's Generic | Time
Mylan piles generic Copaxone pain on Teva as partner Synthon nabs EU green light | Fierce Pharma
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Generici, da Teva Opa su Mylan - Pharmaretail
Teva offers to buy Mylan in $40 billion deal | The Times of Israel
Teva prices EpiPen generic at $300, same price as Mylan generic-Business News , Firstpost
US lawmakers push Mylan, Teva over drug pricing probe - www.israelhayom.com
Teva loses Copaxone patent dispute case to Mylan in UK - Pharmaceutical Business review
Drugmaker Teva makes $40B bid for rival Mylan
Farmaceutica, i generici di Teva lanciano una maxi offerta da 40,1 miliardi per Mylan - la Repubblica
With Teva Bid Off the Table, Mylan's Stock In 'Show-Me' Mode - WSJ
Teva plans competitor for Mylan's EpiPen - Drug Delivery Business
How a Teva-Mylan deal will affect Indian pharma companies | Mint
How Mylan tried to keep Teva from selling a generic EpiPen
In blow to Teva, UK court rules in favor of Copaxone patent challenge | The Times of Israel
Israel s Teva Makes 40 Billion Takeover Bid For Mylan - BW Businessworld
Farmaceutico: Teva ci riprova con Mylan, verso rialzo offerta fino almeno a 43 mld $
Teva Pharmaceutical Industries' quest to acquire Mylan NV could wind up in a Dutch court - Pittsburgh Business Times
Teva makes $40.1 billion takeover bid for Mylan | Mint
